Last reviewed · How we verify

oral resveratrol

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

oral resveratrol is a polyphenol Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Cardiovascular disease prevention.

Resveratrol acts as an activator of SIRT1, a protein that plays a role in cellular regulation and metabolism.

Resveratrol acts as an activator of SIRT1, a protein that plays a role in cellular regulation and metabolism. Used for Cardiovascular disease prevention.

At a glance

Generic nameoral resveratrol
SponsorAssistance Publique - Hôpitaux de Paris
Drug classpolyphenol
TargetSIRT1
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Resveratrol's activation of SIRT1 has been shown to have anti-inflammatory and anti-aging effects. This is thought to occur through the regulation of various cellular pathways, including those involved in metabolism and stress resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oral resveratrol

What is oral resveratrol?

oral resveratrol is a polyphenol drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Cardiovascular disease prevention.

How does oral resveratrol work?

Resveratrol acts as an activator of SIRT1, a protein that plays a role in cellular regulation and metabolism.

What is oral resveratrol used for?

oral resveratrol is indicated for Cardiovascular disease prevention.

Who makes oral resveratrol?

oral resveratrol is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What drug class is oral resveratrol in?

oral resveratrol belongs to the polyphenol class. See all polyphenol drugs at /class/polyphenol.

What development phase is oral resveratrol in?

oral resveratrol is in Phase 3.

What are the side effects of oral resveratrol?

Common side effects of oral resveratrol include Gastrointestinal upset.

What does oral resveratrol target?

oral resveratrol targets SIRT1 and is a polyphenol.

Related